连花清瘟胶囊联合头孢克洛胶囊治疗上呼吸道感染的临床效果观察

Clinical Effect of Lianhua Qingwen Capsules Combined with Cefaclor Capsules in the Treatment of Upper Respiratory Tract Infection

摘要: 背景：近几年来上呼吸道疾病发病率在全球范围内普遍较高，抗病毒和抗生素被大范围和较大剂量的使用，找到合理、有效、安全的治疗方法是本文研究的意义。目的：探讨连花清瘟胶囊与头孢克洛胶囊联合用于治疗急性上呼吸道感染的有效性。方法：2023年1月至2023年6月，浙江警官职业学院卫生所接收了76例病例，并将其随机地分成两个组，即对照组和治疗组，每个组38例。研究中，参与对照组病人需要在3次餐后立即服用头孢克洛胶囊，每次剂量为250毫克。治疗组患者在对照组的基础上口服连花清瘟胶囊4粒，饭前或饭后30 min服用，每天3次。结果：经过7 d的持续治疗，两组病人的临床表现显著不同，其中治疗组的病情明显改善，而另一组的病情则没有显著改善。经过系列检测，两组的血清白细胞介素IL-18、CRP、WBC等指标均显著降低，其中治疗组的降低幅度达到了97.37%，显著高于另一组，具备显著的统计重要性(P < 0.05)。经过治疗，两组患者的体温恢复正常、咳嗽减轻、咽部红肿减轻的速度明显快于未经治疗的组别，这些结果具备统计上的显著性(P < 0.05)。此外，两组患者的血清IL-18、CRP、WBC也明显下降，这些结果也具备一定的统计上的显著性(P < 0.05)。结论：连花清瘟胶囊与头孢克洛胶囊结合使用，可以显著改善急性上呼吸道感染的病情，显著降低患者的病痛，且该方法的安全性极高。

Abstract: Background: In recent years, the incidence of upper respiratory tract diseases has been generally high worldwide, and antiviruses and antibiotics have been used in large and large doses, and it is the significance of this study to find a reasonable, effective and safe treatment. Objective: To investigate the effectiveness of Lianhua Qingwen capsules combined with cefaclor capsules in the treatment of acute upper respiratory tract infection. Methods: From January 2023 to June 2023, 76 cases were accepted at the Health Clinic of Zhejiang Police Vocational Academy and randomly divided into two groups, namely control group and treatment group, with 38 cases in each group. In the study, patients in the participating control group were required to take cefaclor capsules at a dose of 250 mg each time immediately after 3 meals. Patients in the treatment group took 4 capsules orally on the basis of the control group, taken 30 min before or after meals, 3 times a day. Results: After 7 days of continuous treatment, the clinical manifestations of the two groups were significantly different, with the treatment group significantly improving the condition and the other group not significantly improving. After a series of tests, serum interleukin IL-18, CRP, WBC and other indexes in both groups were significantly reduced, and the reduction rate in the treatment group reached 97.37%, which was significantly higher than that of the other group and had significant statistical importance (P < 0.05). After treatment, the two groups returned to normal body temperature, cough reduction, and pharyngeal redness and swelling significantly faster than the untreated group, and these results were statistically significant (P < 0.05). In addition, serum IL-18, CRP, and WBC also decreased significantly in both groups, and these results also had some statistical significance (P < 0.05). Conclusion: The combination of Lianhua Qingwen capsules and cefaclor capsules can significantly improve the condition of acute upper respiratory tract infection and significantly reduce the pain of patients, and the safety of this method is extremely high.